BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart

BioCardia, Inc. (NASDAQ: BCDA) has completed its revised Pre-Submission to the FDA's Center for Devices and Radiological Health under the Q-Submission program. This submission is aimed at obtaining approval for its Helix Catheter, which is designed for the delivery of therapeutic and diagnostic agents to the heart.